Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial.
Gupta AA, Tinker A, Jonker D, Jamal R, Hirte H, Winquist EW, Chu Q, Kollmannsberger C, Wong R, Alcindor T, Nielsen TO, Tsao M, Cottrell TR, Provencher D, Hilton J, Krzyżanowska MK, Elser C, Hotte S, Sederias J, Zhang S, Tu W, Dancey J.
Gupta AA, et al. Among authors: tinker a.
EClinicalMedicine. 2024 Dec 10;79:102991. doi: 10.1016/j.eclinm.2024.102991. eCollection 2025 Jan.
EClinicalMedicine. 2024.
PMID: 39737219
Free PMC article.